

according to Regulation (EC) No. 1907/2006

Desloratadine Liquid Formulation

Version 1.12	Revision Date: 09.04.2021	SDS Number: 778690-00013	Date of last issue: 01.10.2020 Date of first issue: 23.06.2016			
SECTION	1: Identification o	of the substance/r	nixture and of the company/undertaking			
1.1 Product identifier Trade name : Desloratadine Liquid Formulation						
1.2 Relevant identified uses of the substance or mixture and uses advised against						
	of the Sub- e/Mixture	: Pharmaceuti	cal			

1.3 Details of the supplier of the safety data sheet

Company	:	Organon & Co. 30 Hudson Street, 33nd floor 07302 Jersey City, New Jersey, U.S.A
Telephone	:	551-430-6000
E-mail address of person responsible for the SDS	:	EHSSTEWARD@organon.com

1.4 Emergency telephone number

215-631-6999

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Not a hazardous substance or mixture.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

Not a hazardous substance or mixture.

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.



according to Regulation (EC) No. 1907/2006

Desloratadine Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 01.10.2020
1.12	09.04.2021	778690-00013	Date of first issue: 23.06.2016

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

oomponents			
Chemical name	CAS-No.	Classification	Concentration
	EC-No.		(% w/w)
	Index-No.		. ,
	Registration number		
Desloratadine	100643-71-8	Acute Tox. 4; H302	>= 0.025 - <
		Eye Dam. 1; H318	0.1
		Repr. 2; H361fd	
		Aquatic Chronic 2;	
		H411	

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

Protection of first-aiders	:	No special precautions are necessary for first aid responders.
If inhaled	:	If inhaled, remove to fresh air. Get medical attention if symptoms occur.
In case of skin contact	:	Wash with water and soap as a precaution. Get medical attention if symptoms occur.
In case of eye contact	:	Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.
If swallowed	:	If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

None known.


4.3 Indication of any immediate medical attention and special treatment needed

Treatment

: Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical Unsuitable extinguishing
media : None known.





Desloratadine Liquid Formulation

Versi		Revision Date:		S Number:	Date of last issue: 01.10.2020
1.12		09.04.2021	11	8690-00013	Date of first issue: 23.06.2016
5.2 S	special	hazards arising from	the	substance or mix	tture
	Specific fighting	-	:	Exposure to comb	ustion products may be a hazard to health.
	Hazard ucts	ous combustion prod-	:	Carbon oxides	
5.3 A	dvice f	or firefighters			
	Special for firefi	protective equipment ghters	:		ed breathing apparatus for firefighting if nec- nal protective equipment.
	Specific ods	extinguishing meth-	:	cumstances and t Use water spray to	measures that are appropriate to local cir- he surrounding environment. o cool unopened containers. ged containers from fire area if it is safe to do

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions	:	Follow safe handling advice (see section 7) and personal pro- tective equipment recommendations (see section 8).
6.2 Environmental precautions		
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g. by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

	be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absor- bent. Local or national regulations may apply to releases and dis- posal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter- mine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.
--	---

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

according to Regulation (EC) No. 1907/2006



Desloratadine Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 01.10.2020
1.12	09.04.2021	778690-00013	Date of first issue: 23.06.2016

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures	:	See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
Local/Total ventilation	:	Use only with adequate ventilation.
Advice on safe handling	:	Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
		Take care to prevent spills, waste and minimize release to the environment.
Hygiene measures	:	If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami- nated clothing before re-use.
7.2 Conditions for safe storage,	incl	luding any incompatibilities
Requirements for storage areas and containers	:	Keep in properly labelled containers. Store in accordance with the particular national regulations.
Advice on common storage	:	Do not store with the following product types: Strong oxidizing agents
7.3 Specific end use(s)		
Specific use(s)	:	No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis			
Propylene glycol	57-55-6	OELV - 8 hrs (TWA) (particles)	10 mg/m3	IE OEL			
		Further information: Where no specific short-term exposure limit is listed, a figure three times the long-term exposure limit value should be used					
		OELV - 8 hrs (TWA) (total (va- pour and parti- cles))	150 ppm 470 mg/m3	IE OEL			
	Further information: Where no specific short-term exposure limit is listed, a figure three times the long-term exposure limit value should be used						
Desloratadine	100643-71- 8	TWA	20 µg/m3 (OEB 3)	Internal			
		Wipe limit	200 µg/100 cm ²	Internal			

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:





Desloratadine Liquid Formulation

Ver 1.1					f last issue: 01.10.2020 f first issue: 23.06.2016		
	Substa	ance name	End Use	Exposure	routes	Potential health ef- fects	Value
	Propylene glycol		Workers	Inhalation Inhalation		Long-term local ef- fects	10 mg/m3
			Workers			Long-term systemic effects	168 mg/m3
			Consumers	Inhalation		Long-term local ef- fects	10 mg/m3
			Consumers	Inhalatior]	Long-term systemic effects	50 mg/m3

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:

Substance name	Environmental Compartment	Value
Propylene glycol	Fresh water	260 mg/l
	Marine water	26 mg/l
	Intermittent use/release	183 mg/l
	Sewage treatment plant	20000 mg/l
	Fresh water sediment	572 mg/kg
	Marine sediment	57.2 mg/kg
	Soil	50 mg/kg

8.2 Exposure controls

Engineering measures

Ensure adequate ventilation, especially in confined areas. Minimize workplace exposure concentrations.

Personal protective equipment						
Eye protection	: Wear the following personal protective equipment: Safety glasses Equipment should conform to I.S. EN 166					
Hand protection						
Remarks Skin and body protection Respiratory protection	 Wash hands before breaks and at the end of workday. Skin should be washed after contact. If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection. Equipment should conform to I.S. EN 143 					
Filter type	: Particulates type (P)					

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state	:	liquid
Colour	:	clear
Odour	:	sweet
Odour Threshold	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flammability (solid, gas)	:	Not applicable

according to Regulation (EC) No. 1907/2006




Desloratadine Liquid Formulation

Vers 1.12		Revision Date: 09.04.2021		S Number: 3690-00013	Date of last issue: 01.10.2020 Date of first issue: 23.06.2016
	Flomm	ability (liquids)		No data available	
	Flamma	ability (liquids)	:	NO data available	3
		explosion limit / Upper bility limit	:	No data available	
		explosion limit / Lower bility limit	:	No data available	9
	Flash p	point	:	No data available	
	Auto-ig	nition temperature	:	No data available	9
		position temperature omposition tempera-	:	No data available)
	рН		:	No data available)
	Viscosi Visc	ty cosity, dynamic	:	No data available)
	Visc	cosity, kinematic	:	No data available)
	Solubili Wat	ty(ies) er solubility	:	soluble	
	Partitio octanol	n coefficient: n-	:	No data available	9
		pressure	:	No data available	9
	Relative	e density	:	No data available)
	Density	/	:	No data available	9
	Relative	e vapour density	:	No data available	9
		e characteristics iicle size	:	No data available	9
9.2 0	Other in	formation			
	Explosi	ves	:	Not explosive	
	Oxidizir	ng properties	:	The substance of	r mixture is not classified as oxidizing.
	Evapor	ation rate	:	No data available	9
	Molecu	lar weight	:	No data available	9

SECTION 10: Stability and reactivity

10.1 Reactivity


Not classified as a reactivity hazard.





Desloratadine Liquid Formulation

Version 1.12	Revision Date: 09.04.2021		OS Number: 8690-00013	Date of last issue: 01.10.2020 Date of first issue: 23.06.2016		
	n ical stability e under normal conditi	ions.				
10.3 Poss	ibility of hazardous r	reacti	ons			
Hazardous reactions : Can react with strong oxidizing agents.						
10.4 Cond	litions to avoid					
Condi	itions to avoid	:	None known.			
10.5 Incor	npatible materials					
Mater	ials to avoid	:	Oxidizing agen	ts		
	rdous decomposition	-				
SECTION	111: Toxicological	infor	mation			
expos	nation on likely routes sure e toxicity	of :	Inhalation Skin contact Ingestion Eye contact			
	assified based on ava	ilable	information.			
<u>Com</u>	ponents:					
Desic	oratadine:					
Acute	oral toxicity	:	LD50 (Rat): > 5	49 mg/kg		
			LD50 (Mouse):	353 mg/kg		
			LD50 (Monkey) Symptoms: Vor Remarks: No m			
	corrosion/irritation assified based on ava	ilable	information.			
<u>Com</u>	oonents:					
Deslo	oratadine:					
Speci Resul		:	Rabbit No skin irritatior	ı		
	us eye damage/eye i assified based on ava					





Desloratadine Liquid Formulation

sion 2	Revision Date: 09.04.2021	SDS Number: 778690-00013	
<u>Comp</u>	oonents:		
Deslo	pratadine:		
Speci	es	: Rabbit	
Rema		: Severe ey	e irritation
Resp	iratory or skin sensi	tisation	
Skin	sensitisation		
Not cl	assified based on ava	ailable information	
-	iratory sensitisation assified based on ava		
	oonents:		
	pratadine:		
Test 1		: Maximisat	ion Test
Expos	sure routes	: Dermal	
Speci Resul		: Guinea pio : negative	9
	cell mutagenicity assified based on ava	ailable information	
<u>Comp</u>	<u>oonents:</u>		
Deslo	oratadine:		
		: Test Type Result: ne	: Bacterial reverse mutation assay (AMES) gative
	oratadine:	Result: ne Test Type	gative : Chromosomal aberration m: Human lymphocytes
Geno	oratadine:	Result: ne Test Type Test syste Result: ne : Test Type	gative : Chromosomal aberration m: Human lymphocytes gative : Micronucleus test
Geno	bratadine: toxicity in vitro	Result: ne Test Type Test syste Result: ne : Test Type Species: M	gative : Chromosomal aberration m: Human lymphocytes gative : Micronucleus test Aouse
Geno	bratadine: toxicity in vitro	Result: ne Test Type Test syste Result: ne : Test Type Species: M Cell type:	gative : Chromosomal aberration m: Human lymphocytes gative : Micronucleus test <i>I</i> ouse Bone marrow
Geno	bratadine: toxicity in vitro	Result: ne Test Type Test syste Result: ne : Test Type Species: M Cell type:	gative : Chromosomal aberration m: Human lymphocytes gative : Micronucleus test <i>N</i> ouse Bone marrow n Route: Oral
Geno	toxicity in vitro	Result: ne Test Type Test syste Result: ne : Test Type Species: N Cell type: Application	gative : Chromosomal aberration m: Human lymphocytes gative : Micronucleus test <i>N</i> ouse Bone marrow n Route: Oral
Geno	bratadine: toxicity in vitro	Result: ne Test Type Test syste Result: ne : Test Type Species: N Cell type: Application Result: ne	gative : Chromosomal aberration m: Human lymphocytes gative : Micronucleus test <i>N</i> ouse Bone marrow n Route: Oral gative
Geno Geno Carci Not cl	bratadine: toxicity in vitro toxicity in vivo nogenicity	Result: ne Test Type Test syste Result: ne : Test Type Species: N Cell type: Application Result: ne	gative : Chromosomal aberration m: Human lymphocytes gative : Micronucleus test <i>N</i> ouse Bone marrow n Route: Oral gative
Geno Geno Carci Not cl <u>Comp</u>	bratadine: toxicity in vitro toxicity in vivo nogenicity	Result: ne Test Type Test syste Result: ne : Test Type Species: N Cell type: Application Result: ne	gative : Chromosomal aberration m: Human lymphocytes gative : Micronucleus test <i>N</i> ouse Bone marrow n Route: Oral gative
Genor Genor Carci Not cl <u>Comp</u> Desic Speci	bratadine: toxicity in vitro toxicity in vivo nogenicity lassified based on ava <u>conents:</u> bratadine: es	Result: ne Test Type Test syste Result: ne : Test Type Species: M Cell type: Application Result: ne ailable information	gative : Chromosomal aberration m: Human lymphocytes gative : Micronucleus test <i>N</i> ouse Bone marrow n Route: Oral gative
Genor Genor Carci Not cl <u>Comp</u> Desic Speci Applic	toxicity in vitro toxicity in vitro toxicity in vivo assified based on ava <u>conents:</u> pratadine: es cation Route	Result: ne Test Type Test syste Result: ne : Test Type Species: M Cell type: Application Result: ne ailable information : Mouse : Oral	gative : Chromosomal aberration m: Human lymphocytes gative : Micronucleus test <i>N</i> ouse Bone marrow n Route: Oral gative
Genor Genor Carci Not cl <u>Comp</u> Desic Speci Applic	toxicity in vitro toxicity in vitro toxicity in vivo nogenicity assified based on ava <u>conents:</u> pratadine: es cation Route sure time	Result: ne Test Type Test syste Result: ne : Test Type Species: M Cell type: Application Result: ne ailable information	gative : Chromosomal aberration m: Human lymphocytes gative : Micronucleus test <i>N</i> ouse Bone marrow n Route: Oral gative

according to Regulation (EC) No. 1907/2006



Desloratadine Liquid Formulation

Version 1.12	Revision Date: 09.04.2021	SDS Number: 778690-00013	Date of last issue: 01.10.2020 Date of first issue: 23.06.2016		
Re: Tai	AEL sult get Organs marks	 10 mg/kg body weight equivocal Liver Based on data from similar materials The mechanism or mode of action may not be relevant in h mans. 			
	productive toxicity classified based on avai	lable information.			
<u>Co</u>	mponents:				
	sloratadine: ects on fertility	Symptoms: R Result: positiv	male oute: Oral EL: 12 mg/kg body weight educed fertility /e e mechanism or mode of action may not be rele-		
			female EL: 3 mg/kg body weight o effects on fertility		
Eff me	ects on foetal develop- nt	Species: Rab Application R Development			
		Species: Rat Application R Development Symptoms: P Result: Speci	al Toxicity: LOAEL: 9 mg/kg body weight reimplantation loss, Reduced body weight fic developmental abnormalities e mechanism or mode of action may not be rele-		
		Species: Rat Application R	al Toxicity: LOAEL: 18 mg/kg body weight		
	productive toxicity - As- sment	fertility, based	ce of adverse effects on sexual function and d on animal experiments., Some evidence of ts on development, based on animal experi-		

according to Regulation (EC) No. 1907/2006



Desloratadine Liquid Formulation

Version 1.12	Revision Date: 09.04.2021	SDS Number: 778690-00013	Date of last issue: 01.10.2020 Date of first issue: 23.06.2016						
Not cla	STOT - single exposure Not classified based on available information.								
	STOT - repeated exposure								
	Not classified based on available information.								
-	Repeated dose toxicity								
Comp	onents:								
Specie LOAE Applic Expos	L ation Route ure time t Organs		ity observed in testing n or mode of action may not be relevant in hu-						
Expos	L L ation Route ure time t Organs	: Monkey : 6 mg/kg : 12 mg/kg : Oral : 3 Months : Central nervous : Gastrointestinal	s system disturbance						
	L ation Route ure time	: Monkey : 40 mg/kg : Oral : 17 Months : No significant a	dverse effects were reported						
	L ation Route ure time	: Monkey : 6 mg/kg : Oral : 3 Months : Gastrointestinal	disturbance, Fatigue						

Aspiration toxicity


Not classified based on available information.

11.2 Information on other hazards

Endocrine disrupting properties

Product:

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.





Desloratadine Liquid Formulation

Vers 1.12		Revision Date: 09.04.2021		9S Number: 8690-00013	Date of last issue: 01.10.2020 Date of first issue: 23.06.2016			
	Experience with human exposure							
	Compo	onents:						
	Deslor Inhalati Eye cor Ingestio	ntact	 Remarks: May cause respiratory tract irritation. Symptoms: Eye irritation Symptoms: dry mouth, muscle pain, Fatigue, Drowsines sore throat, painful menstration 					
SEC	SECTION 12: Ecological information							
12.1	Toxicit	ÿ						
	Compo	onents:						
	Deslor	atadine:						
	Toxicity	<i>r</i> to fish	:	LC50 (Lepomis m Exposure time: 96 Method: FDA 4.11				
		v to daphnia and other invertebrates	:	EC50 (Daphnia m Exposure time: 48 Method: FDA 4.08				
	Toxicity plants	v to algae/aquatic	:	EC50 (Pseudokiro mg/l Exposure time: 72 Method: OECD Te				
				NOEC (Pseudokir mg/l Exposure time: 72 Method: OECD Te				
	Toxicity	v to microorganisms	:	EC50 (Natural mic Exposure time: 3 I Test Type: Respir Method: OECD Te	ation inhibition			
				NOEC (Natural mi Exposure time: 3 I Test Type: Respir Method: OECD Te	ation inhibition			
	Toxicity icity)	v to fish (Chronic tox-	:	NOEC: 0.12 mg/l Exposure time: 32 Species: Pimepha Method: OECD Te	les promelas (fathead minnow)			
		v to daphnia and other invertebrates (Chron- ity)	:	NOEC: 0.48 mg/l Exposure time: 21 Species: Daphnia Method: OECD Te	magna (Water flea)			

according to Regulation (EC) No. 1907/2006




Desloratadine Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 01.10.2020
1.12	09.04.2021	778690-00013	Date of first issue: 23.06.2016

12.2 Persistence and degradability

	Components:					
	Desloratadine: Biodegradability	:	Result: Not readily biodegradable. Biodegradation: 67.4 % Exposure time: 28 d Method: OECD Test Guideline 314			
			Result: Not readily biodegradable. Biodegradation: 0 % Exposure time: 28 d Method: FDA 3.11			
	Stability in water	:	Hydrolysis: < 10 % at 50 °C(5 d) Method: FDA 3.09			
12.3	Bioaccumulative potential					
	Components:					
	Desloratadine: Partition coefficient: n- octanol/water	:	log Pow: 1.24 Method: OECD Test Guideline 107			
12.4	Mobility in soil					
	Components:					
	Desloratadine:					
	Distribution among environ- mental compartments	:	log Koc: 3.00 Method: OECD Test Guideline 106			
12.5	Results of PBT and vPvB as	ses	ssment			
	Product:					
	Assessment	:	This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.			
12.6	12.6 Endocrine disrupting properties					
	Product:					
	Assessment	:	The substance/mixture does not contain components consid- ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.			





Desloratadine Liquid Formulation

Version 1.12	Revision Date: 09.04.2021	SDS Number: 778690-00013	Date of last issue: 01.10.2020 Date of first issue: 23.06.2016				
	12.7 Other adverse effects No data available						
SECTION	SECTION 13: Disposal considerations						
13.1 Waste	e treatment methods						
Produ	ct	According to the are not product s Waste codes sho	ordance with local regulations. European Waste Catalogue, Waste Codes pecific, but application specific. buld be assigned by the user, preferably in the waste disposal authorities.				
Conta	minated packaging	: Empty containers dling site for recy	should be taken to an approved waste han-				

SECTION 14: Transport information

14.1 UN number or ID number

Not regulated as a dangerous good

14.2 UN proper shipping name

Not regulated as a dangerous good

14.3 Transport hazard class(es)

Not regulated as a dangerous good

14.4 Packing group

Not regulated as a dangerous good

14.5 Environmental hazards

Not regulated as a dangerous good

14.6 Special precautions for user

Not applicable

14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances,	:	Not applicable
preparations and articles (Annex XVII)		
REACH - Candidate List of Substances of Very High	:	Not applicable
Concern for Authorisation (Article 59).		
REACH - List of substances subject to authorisation	:	Not applicable
(Annex XIV)		
Regulation (EC) No 1005/2009 on substances that de-	:	Not applicable
plete the ozone layer		
Regulation (EU) 2019/1021 on persistent organic pollu-	:	Not applicable
tants (recast)		



according to Regulation (EC) No. 1907/2006

Desloratadine Liquid Formulation

Version 1.12	Revision Date: 09.04.2021	SDS N 778690	umber:)-00013	Date of last issue: 01.10.2020 Date of first issue: 23.06.2016			
Regulation (EC) No 649/2012 of the European Parlia- : Not applicable ment and the Council concerning the export and import of dangerous chemicals Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances. Not applicable							
The components of this product are reported in the following inventories:							
AICS		: not	determined				
DSL		: not	determined				
IECS	C	: not	determined				

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information	:	Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.			
Full text of H-Statements					
H302	:	Harmful if swallowed.			
H318	:	Causes serious eye damage.			
H361fd	:	Suspected of damaging fertility. Suspected of damaging the unborn child.			
H411	:	Toxic to aquatic life with long lasting effects.			
Full text of other abbreviations					
Acute Tox.	:	Acute toxicity			
Aquatic Chronic	:	Long-term (chronic) aquatic hazard			
Eye Dam.	:	Serious eye damage			
Repr.	:	Reproductive toxicity			
IE ÔEL	:	Ireland. List of Chemical Agents and Occupational Exposure Limit Values - Schedule 1			
IE OEL / OELV - 8 hrs (TWA)	:	Occupational exposure limit value (8-hour reference period)			

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in



Desloratadine Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 01.10.2020
1.12	09.04.2021	778690-00013	Date of first issue: 23.06.2016

China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL -International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TRGS -Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to compile the Safety Data Sheet

: Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, http://echa.europa.eu/

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IE / EN